Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye co ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearing out, ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5 to 7 percent of their weight had a 58% lower risk of ...